Hamlet Pharma’s achievements regarded as ‘‘exceptional’’ by the European Commission after final review of the Horizon 2020 project
Hamlet Pharma, listed on Spotlight Stock Market, was awarded an EIC Accelerator grant of 2.2 M EURO in the highly competitive Horizon 2020 program. The EIC accelerator program supports individual small and medium enterprises, in particular start ups and spin out companies, to develop and scale up game changing innovations. At the end of January 2023, Hamlet Pharma filed the final report of the work supported by this grant.
In their response, the European Commission stated: “Hamlet Pharma’s Project has delivered exceptional results with significant immediate or potential impact.” The Commission further concluded: “The Project has fully achieved its objectives and milestones for the period. Encouraging clinical data were produced. The treatment was also shown to be safe and no drug-related side effects were observed.’’
The EU reviewers further mention that: “Hamlet Pharma AB is developing a revolutionary cancer treatment on a peptide-based platform for targeting and killing tumor cells with high precision.”
Their evaluation further states that: ‘’Hamlet Pharma’s proprietary drug complex is derived from the human breast milk protein, alpha-lactalbumin, and represents a therapeutic solution with high tumor-killing capacity, high target specificity with no demonstrated toxicity killing more than 40 different types of tumor cells. The EU-funded project will advance this drug complex, in combination with the synthetic drug candidate Alpha1H, into clinical development as an early-stage treatment for bladder cancer, which has the highest recurrence rate among all cancer types.
In the final reporting period of this project, the Phase I/II study of Alpha1H in bladder cancer patients was completed and the final study report was submitted. Encouraging clinical data were produced. The treatment was also shown to be safe and no drug-related side effects were observed. The results were published in Nature Communication 2021. Importantly, the company has now engaged in regulatory dialogue with FDA and EMA. This is a critical step to ensuring the completeness of the data generated so far and to secure input in the study design for the Phase III study.
The company has also undertaken a project valuation and Health Technology assessment and the results are encouraging. However, these data will need to be validated at a later stage with the Health Technology Assessment bodies in Europe and also in the US.”
‘’To be labeled exceptional by the European Commission is a great honor and an acknowledgement of the quality of the drug development process in Hamlet Pharma’’, says Catharina Svanborg, Founder and Chairman of the Board.
For more information, contact
Catharina Svanborg, Chairman and founder of Hamlet Pharma, +46 709 42 65 49
Martin Erixon, CEO of Hamlet Pharma, +46-733 00 43 77
About Hamlet Pharma
Hamlet Pharma, listed on Spotlight, develops new drugs for the treatment and prevention of cancer, based on the discovery of the tumoricidal protein-lipid complex, HAMLET. HAMLET has shown therapeutic efficacy in animal models and effects in clinical proof-of-concept studies. The Alpha1H peptide drug candidate, reproduces the effects of HAMLET and has demonstrated therapeutic efficacy in patients with bladder cancer, where cinical trials are ongoing. Bladder cancer is a common and costly form of cancer, with few successful new treatment options. The company is further exploring the use of Alpha1H for other cancer indications, including brain tumors. In addition, Hamlet Pharma develops BAMLET, which is a HAMLET-like complex formed by bovine α-lactalbumin. Data from animal models show promising effects of local BAMLET treatment against colon cancer.
VibroSense Dynamics AB beslutar om riktad emission av B-aktier till garanter i samband med avslutad företrädesemission
VibroSense Dynamics AB (publ) ("VibroSense" eller "Bolaget") har slutfört den företrädesemission av B-aktier som beslutades av Bolagets styrelse den 9 februari 2023 (”Företrädesemissionen”). I samband härmed genomförs, i enlighet med de garantiavtal som ingåtts och som tidigare kommunicerats, en rik...
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Dublin, Ireland, March 22, 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that all resolutions presented to shareholders at today’s...
Sista dag för handel med BTA i PolarCool
Företrädesemissionen i PolarCool AB (publ) (”PolarCool” eller ”Bolaget”) är nu registrerad hos Bolagsverket och betalda tecknade aktier (BTA) kommer därmed att omvandlas till aktier. Sista dag för handel med BTA är den 27 mars 2023. Avstämningsdag hos Euroclear är den 29 mars 2023, varefter BTA omva...
Gabather AB (publ) meddelar sista dag för handel med BTA
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL STORBRITANNIEN, USA, KANADA, JAPAN AUSTRALIEN, HONGKONG, NYA ZEELAND, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS, SCHWEIZ, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIO...